BGP-13618

BGP-13618 is an experimental **small-molecule covalent inhibitor of PAX8** reported by BridGene Biosciences. Publicly available sponsor material identifies it as a discovery-stage compound found using BridGene's IMTAC chemoproteomics platform and states that it disrupts the DNA-binding activity of **paired box protein Pax-8**, a lineage-associated transcription factor implicated in ovarian cancer and renal cell carcinoma. Based on the available public evidence, BGP-13618 appears to be an early preclinical oncology program rather than a clinical-stage drug, and detailed pharmacology, binding-site residue data, formulation, route, and disease-specific development stage have not been publicly disclosed for this exact code.